Novel treatments for AD are expected to become ‘blockbuster’ medicines. The AD market has been relatively stable, dominated by the symptomatic acetylcholine esterase (AChE) inhibitors. Datamonitor predicted that the market would grow from USD 5.3bn in 2011 to more than USD 12bn beyond 2021 at a CAGR of 9.1%. The introduction of novel disease-modifying therapies has the potential to become real blockbuster with annual sales of more than USD 1bn if successful. The top selling AChE inhibitor drug, Aricept had peak annual sales of USD 3.5bn, clearly demonstrating the commercial potential of a novel drug for dementia.
Pharmasum Therapeutics aims to develop novel, differentiated drugs and partner these for late-stage development. The company may reserve commercial rights in certain territories.